# Pharmacokinetics of Micafungin Given Twice Weekly Intravenously Compared to Micafungin Given Daily to Patients at Risk for Developing an Invasive Fungal Disease

> **NCT02172768** · PHASE2 · COMPLETED · sponsor: **Radboud University Medical Center** · enrollment: 30 (actual)

## Conditions studied

- Acute Graft Versus Host Disease Grade II-IV
- Allogeneic Stem Cell Transplant
- Acute Myeloid Leucaemia
- Myelo Dysplastic Syndrome

## Interventions

- **OTHER:** alternate dosing
- **OTHER:** daily dosing
- **DRUG:** micafungin

## Key facts

- **NCT ID:** NCT02172768
- **Lead sponsor:** Radboud University Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-10
- **Primary completion:** 2016-06
- **Final completion:** 2016-07
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2020-12-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02172768

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02172768, "Pharmacokinetics of Micafungin Given Twice Weekly Intravenously Compared to Micafungin Given Daily to Patients at Risk for Developing an Invasive Fungal Disease". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02172768. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*